Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with non‐specific low‐back pain (LBP)
1 finding from 1 review
Disability long term Oswestry; 100‐point scale where 0 equals no disability and 100 is seriously disabled. · patients with non‐specific low‐back pain (LBP)
1 finding from 1 review
General well‐being · patients with non‐specific low‐back pain (LBP)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events · patients with non‐specific low‐back pain (LBP)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
CI: Confidence interval · patients with non‐specific low‐back pain (LBP)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with non‐specific low‐back pain (LBP)
1 finding from 1 review
Functional ability · patients with non‐specific low‐back pain (LBP)
1 finding from 1 review
Functional ability · patients with non‐specific low‐back pain (LBP)
2 findings from 1 review
General well‐being · patients with non‐specific low‐back pain (LBP)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with non‐specific low‐back pain (LBP)
1 finding from 1 review
Adverse events · patients with non‐specific low‐back pain (LBP)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
CI: Confidence interval · patients with non‐specific low‐back pain (LBP)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Camomile showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Indigo wood root showed no clear difference in oral mucositis (moderate to severe) compared with saline (placebo); GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate showed no clear difference in oral mucositis (any severity) compared with placebo/usual care (moderate certainty).
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Intestinal trefoil factor showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Zinc sulphate led to lower oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Glutamine showed no clear difference in oral mucositis (any severity) compared with placebo/usual care; GRADE not reported.
1 finding from 1 review
RR 0.78 [0.57, 1.08]
5 studies
GRADE not reported
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc led to lower oral mucositis (moderate to severe) compared with azulene; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Sucralfate probably leads to lower oral mucositis (severe) compared with placebo/usual care (moderate certainty).
1 finding from 1 review